1022150-12-4 Usage
Description
3-(4-Phenoxy-phenyl)-1-piperidin-3-yl-1H-pyrazolo[3,4-d]pyriMidin-4-ylaMine, also known as IBT6A, is a Btk kinase inhibitor and a precursor compound used in the synthesis of Ibrutinib, a drug that targets Bruton's tyrosine kinase. It plays a crucial role in the development of pyrazolo-pyrimidine compounds, which have potential applications in various therapeutic areas.
Uses
Used in Pharmaceutical Industry:
3-(4-Phenoxy-phenyl)-1-piperidin-3-yl-1H-pyrazolo[3,4-d]pyriMidin-4-ylaMine is used as an intermediate for the synthesis of pyrazolo-pyrimidine compounds, specifically for the preparation of Ibrutinib (I124970) derivatives. These compounds are known to inhibit Bruton's tyrosine kinase, a target enzyme involved in various cellular processes, including cell proliferation, survival, and migration.
As an intermediate in the production of Ibrutinib, 3-(4-Phenoxy-phenyl)-1-piperidin-3-yl-1H-pyrazolo[3,4-d]pyriMidin-4-ylaMine contributes to the development of treatments for various diseases, such as cancer and autoimmune disorders, where Bruton's tyrosine kinase plays a significant role in their progression.
Check Digit Verification of cas no
The CAS Registry Mumber 1022150-12-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,2,1,5 and 0 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1022150-12:
(9*1)+(8*0)+(7*2)+(6*2)+(5*1)+(4*5)+(3*0)+(2*1)+(1*2)=64
64 % 10 = 4
So 1022150-12-4 is a valid CAS Registry Number.
InChI:InChI=1S/C22H22N6O/c23-21-19-20(15-8-10-18(11-9-15)29-17-6-2-1-3-7-17)27-28(22(19)26-14-25-21)16-5-4-12-24-13-16/h1-3,6-11,14,16,24H,4-5,12-13H2,(H2,23,25,26)
1022150-12-4Relevant articles and documents
A synthetic method of ibutinib
-
, (2022/03/02)
The present invention provides a preparation method of ibutinib and its application, by optimizing the feeding ratio and reaction conditions, increasing the purification step of the intermediate, and the use of inorganic alkali instead of organic base as an acid binding agent, significantly reducing the impurity content of ibutinib synthetic intermediates and final products, especially the content of isomer impurities, to ensure the quality of drugs and clinical drug safety provides a strong guarantee.
PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR
-
, (2020/12/07)
Disclosed is a process for the preparation of certain intermediates, e.g. process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form, which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.
PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR
-
, (2020/12/07)
Disclosed is a process for the preparation of certain intermediates, e.g. a process for preparing a compound of formula (I) wherein, R1, R2 and X1 are as defined in the description, and which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.